View Financial HealthBio Plus 配当と自社株買い配当金 基準チェック /16Bio Plus配当を支払う会社であり、現在の利回りは1.51%です。主要情報1.5%配当利回り-2.9%バイバック利回り総株主利回り-1.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).分析記事 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).お知らせ • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.すべての更新を表示Recent updatesNew Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin).Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.2% over the past three years.お知らせ • Mar 10Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,550, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 35% over the past three years.New Risk • Feb 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.0% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (17% net profit margin).分析記事 • Jan 30Is Bio Plus (KOSDAQ:099430) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).分析記事 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...分析記事 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Medical Equipment industry in South Korea. Total loss to shareholders of 9.0% over the past three years.New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (18% net profit margin).分析記事 • Aug 18Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 22Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't IdealThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...分析記事 • May 09What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling YouBio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders have had their patience rewarded with a 26% share price jump in the...Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩8,020, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 8.8% over the past three years.分析記事 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...New Risk • Mar 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 39% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (68% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).お知らせ • Feb 28Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩7,170, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 16% over the past three years.分析記事 • Feb 14Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 07Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch UpDespite an already strong run, Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have been powering on, with a gain of 30% in...Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).分析記事 • Dec 15Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,880, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past three years.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (69% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change).分析記事 • Nov 23Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For ExitBio Plus Co., Ltd's ( KOSDAQ:099430 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell right...Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,560, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years.お知らせ • Aug 02Bio Plus Co., Ltd announced that it has received KRW 60 billion in fundingOn July 31, 2024, Bio Plus Co., Ltd, closed the transaction.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (54% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).分析記事 • Jul 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have had a really impressive month, gaining 29% after a shaky period...Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,450, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.3% over the past year.分析記事 • Jul 05The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire ConfidenceWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...お知らせ • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.Buy Or Sell Opportunity • Jun 10Now 22% overvaluedOver the last 90 days, the stock has fallen 33% to ₩4,580. The fair value is estimated to be ₩3,756, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%.分析記事 • Jun 08More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders that were waiting for something to happen have been dealt a blow with...Valuation Update With 7 Day Price Move • May 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩5,180, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 19% over the past year.分析記事 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).Buying Opportunity • Oct 19Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be ₩8,126, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Earnings per share has grown by 92%. Revenue is forecast to grow by 84% in 2 years. Earnings is forecast to grow by 63% in the next 2 years.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,870, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩7,559 per share.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,370, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩4,098 per share.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,550, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩11,285 per share.Price Target Changed • Dec 15Price target increased to ₩9,750Up from ₩8,917, the current price target is an average from 3 analysts. New target price is 33% above last closing price of ₩7,330. Stock is up 16% over the past year. The company is forecast to post earnings per share of ₩362 for next year compared to ₩207 last year.Price Target Changed • Nov 16Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 34% above last closing price of ₩28,700. Stock is up 18% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩31,100, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩46,800 per share.Price Target Changed • Nov 02Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₩26,750. Stock is down 0.6% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩24,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩40,006 per share.お知らせ • Oct 07BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in fundingBioPlus Co., Ltd. announced a private placement of 690,845 registered non-voting redeemable convertible preferred shares at issue price of KRW 28,950 per share for gross proceeds of KRW 19,999,962,750? on October 6, 2022. The transaction will include participation from Lindman - Woori Technology Finance Fund No. 13 for 69,084 shares, Lindman Innovation Growth Private Equity Joint Venture for 345,423 shares, and Lindman Asia Fund No. 16 for 276,338 shares. The shares carry rate of interest of 10% per annum. The shares to be issued shall have a hold period of 1 year from the closing of the transaction. The repayment period is from April 25, 2025 to October 24, 2032. The shares are convertible into 690,845 shares of the company from January 25, 2023 to October 24, 2032. The transaction is expected to close on October 24, 2022. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩28,450, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩43,793 per share.決済の安定と成長配当データの取得安定した配当: A099430は 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: A099430は3年間のみ配当金を支払っており、それ以降支払額は増加していません。配当利回り対市場Bio Plus 配当利回り対市場A099430 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A099430)1.5%市場下位25% (KR)1.1%市場トップ25% (KR)4.0%業界平均 (Medical Equipment)2.1%アナリスト予想 (A099430) (最長3年)n/a注目すべき配当: A099430の配当金 ( 1.51% ) はKR市場の配当金支払者の下位 25% ( 1.14% ) よりも高くなっています。高配当: A099430の配当金 ( 1.51% ) はKR市場の配当金支払者の上位 25% ( 4.05% ) と比較すると低いです。株主への利益配当収益カバレッジ: A099430の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A099430は配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YKR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/13 19:43終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio Plus Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Hyung Soo KimHanwha Investment & Securities Co., Ltd.Junghyun KimKyobo Securities Co., LtdJaehee WonShinhan Investment Corp.1 その他のアナリストを表示
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).
分析記事 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...
Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).
お知らせ • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.
New Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin).
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.2% over the past three years.
お知らせ • Mar 10Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,550, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 35% over the past three years.
New Risk • Feb 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.0% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (17% net profit margin).
分析記事 • Jan 30Is Bio Plus (KOSDAQ:099430) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).
分析記事 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...
分析記事 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...
Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Medical Equipment industry in South Korea. Total loss to shareholders of 9.0% over the past three years.
New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (18% net profit margin).
分析記事 • Aug 18Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jul 22Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't IdealThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
分析記事 • May 09What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling YouBio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders have had their patience rewarded with a 26% share price jump in the...
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩8,020, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 8.8% over the past three years.
分析記事 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...
New Risk • Mar 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 39% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (68% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).
お知らせ • Feb 28Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩7,170, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 16% over the past three years.
分析記事 • Feb 14Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 07Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch UpDespite an already strong run, Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have been powering on, with a gain of 30% in...
Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).
分析記事 • Dec 15Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,880, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past three years.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (69% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change).
分析記事 • Nov 23Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For ExitBio Plus Co., Ltd's ( KOSDAQ:099430 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell right...
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,560, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years.
お知らせ • Aug 02Bio Plus Co., Ltd announced that it has received KRW 60 billion in fundingOn July 31, 2024, Bio Plus Co., Ltd, closed the transaction.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (54% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).
分析記事 • Jul 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have had a really impressive month, gaining 29% after a shaky period...
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,450, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.3% over the past year.
分析記事 • Jul 05The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire ConfidenceWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
お知らせ • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.
Buy Or Sell Opportunity • Jun 10Now 22% overvaluedOver the last 90 days, the stock has fallen 33% to ₩4,580. The fair value is estimated to be ₩3,756, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%.
分析記事 • Jun 08More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders that were waiting for something to happen have been dealt a blow with...
Valuation Update With 7 Day Price Move • May 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩5,180, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 19% over the past year.
分析記事 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.
Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).
Buying Opportunity • Oct 19Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be ₩8,126, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Earnings per share has grown by 92%. Revenue is forecast to grow by 84% in 2 years. Earnings is forecast to grow by 63% in the next 2 years.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,870, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩7,559 per share.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,370, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩4,098 per share.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,550, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩11,285 per share.
Price Target Changed • Dec 15Price target increased to ₩9,750Up from ₩8,917, the current price target is an average from 3 analysts. New target price is 33% above last closing price of ₩7,330. Stock is up 16% over the past year. The company is forecast to post earnings per share of ₩362 for next year compared to ₩207 last year.
Price Target Changed • Nov 16Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 34% above last closing price of ₩28,700. Stock is up 18% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩31,100, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩46,800 per share.
Price Target Changed • Nov 02Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₩26,750. Stock is down 0.6% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.
Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩24,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩40,006 per share.
お知らせ • Oct 07BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in fundingBioPlus Co., Ltd. announced a private placement of 690,845 registered non-voting redeemable convertible preferred shares at issue price of KRW 28,950 per share for gross proceeds of KRW 19,999,962,750? on October 6, 2022. The transaction will include participation from Lindman - Woori Technology Finance Fund No. 13 for 69,084 shares, Lindman Innovation Growth Private Equity Joint Venture for 345,423 shares, and Lindman Asia Fund No. 16 for 276,338 shares. The shares carry rate of interest of 10% per annum. The shares to be issued shall have a hold period of 1 year from the closing of the transaction. The repayment period is from April 25, 2025 to October 24, 2032. The shares are convertible into 690,845 shares of the company from January 25, 2023 to October 24, 2032. The transaction is expected to close on October 24, 2022. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩28,450, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩43,793 per share.